EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study

Ubonphan Chaichana iD, Kenneth K C Man iD, Chengsheng Ju iD, Janine Makaronidis iD, Li Wei iD

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf429 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Ubonphan Chaichana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom. Hauptthemen laut MEDLINE: Metformin, COVID-19, Obesity, Overweight. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A subgroup analysis of the COVID-OUT trial's long-term outcome found that starting metformin within 3 days of coronavirus disease 2019 (COVID-19) diagnosis reduced post–COVID-19 condition (PCC) incidence by 63% in overweight or obese individuals. However, its generalizability remains uncertain.

Objectives

To evaluate the effectiveness of metformin in preventing PCC in adults with overweight or obesity who had a recent COVID-19 infection.

Design

A retrospective cohort study using a sequential target trial emulation framework. Data Sources The United Kingdom primary care data from the Clinical Practice Research Datalink Aurum database from March 2020 to July 2023.

Participants

Adults with overweight or obesity (body mass index ≥ 25 kg/m²) and a record of severe acute respiratory syndrome coronavirus 2 infection were included. Exclusions included metformin use in the prior year or metformin contraindications.

Measurements

The outcome was PCC, defined by a PCC diagnostic code or at least 1 World Health Organization–listed symptoms between 90 and 365 days after diagnosis, with no prior history of the symptom within 180 days before infection. The pooled hazard ratio and risk difference for the incidence of PCC were adjust for baseline characteristics.

Results

Among 624 308 patients, 2976 initiated metformin within 90 days of COVID-19 diagnosis. The 1-year risk difference for PCC in the intention-to-treat analysis was −12.58% (hazard ratio 0.36; 95% CI, 0.32–0.41), with consistent results in subgroup analyses.

Limitations

Findings may not apply to individuals with a normal body mass index.

Conclusions

Early metformin treatment in overweight or obese individuals may reduce PCC risk. Further research is needed to confirm causality and clarify metformin's role in PCC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminCOVID-19ObesityOverweightHypoglycemic AgentsHumansRetrospective StudiesFemaleMaleMiddle AgedAdultAgedSARS-CoV-2United KingdomBody Mass Index

Stichwörter der Autor:innen

COVID-19 preventive treatmentPost COVID-19 conditionlong covidmetformin

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Research Department of Practice and Policy, UCL School of Pharmacy, London, United Kingdom.
  • Laboratory of Data Discovery for Health (D24H), Hong Kong Special Administrative Region, China.
  • Centre for Medicines Optimisation Research and Education, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom.
  • Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China.
  • Institute of Cardiovascular Science, University College London, London, United Kingdom.
  • Centre for Obesity Research, Rayne Institute, Department of Medicine, University College London, London, United Kingdom.

ORCID-Profile: Ubonphan Chaichana, Kenneth K C Man, Chengsheng Ju, Janine Makaronidis, Li Wei

Zitieren

APA

Chaichana, U., Man, K. K. C., Ju, C., Makaronidis, J., & Wei, L. (2025). Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf429

Vancouver

Chaichana U, Man KKC, Ju C, Makaronidis J, Wei L. Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf429

BibTeX
@article{Chaichana2025,
  author = {Chaichana, Ubonphan and Man, Kenneth K C and Ju, Chengsheng and Makaronidis, Janine and Wei, Li},
  title = {Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf429}
}
Kostenlos starten →